EBS - Emergent BioSolutions Ridgeback to collaborate for ebola treatment Ebanga
- Emergent BioSolutions ( NYSE: EBS ) on Thursday said it had entered into a collaboration agreement with Ridgeback Biotherapeutics for its FDA-approved ebola treatment Ebanga.
- Ridgeback's Ebanga, a monoclonal antibody, was approved by the U.S. drug regulator in Dec. 2020.
- As per the proposed collaboration, EBS will make, sell and distribute Ebanga in the U.S. and Canada, while Ridgeback will be the global access partner for the treatment.
- Ridgeback Biotherapeutics is known for developing COVID-19 antiviral treatment molnupiravir with Merck ( MRK ).
- EBS stock earlier closed +1.9% at $33.45.
For further details see:
Emergent BioSolutions, Ridgeback to collaborate for ebola treatment Ebanga